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Abstract
Fulvestrant (ICI-182,780) has recently been shown to effectively suppress prostate cancer cell growth in vitro and in vivo. But
it is unclear whether microRNAs play a role in regulating oncogene expression in fulvestrant-treated prostate cancer. Here,
this study reports hsa-miR-765 as the first fulvestrant-driven, ERb-regulated miRNA exhibiting significant tumor suppressor
activities like fulvestrant, against prostate cancer cell growth via blockage of cell-cycle progression at the G2/M transition,
and cell migration and invasion possibly via reduction of filopodia/intense stress-fiber formation. Fulvestrant was shown to
upregulate hsa-miR-765 expression through recruitment of ERb to the 59-regulatory-region of hsa-miR-765. HMGA1, an
oncogenic protein in prostate cancer, was identified as a downstream target of hsa-miR-765 and fulvestrant in cell-based
experiments and a clinical study. Both the antiestrogen and the hsa-miR-765 mimic suppressed HMGA1 protein expression.
In a neo-adjuvant study, levels of hsa-miR-765 were increased and HMGA1 expression was almost completely lost in prostate
cancer specimens from patients treated with a single dose (250 mg) of fulvestrant 28 days before prostatectomy. These
findings reveal a novel fulvestrant signaling cascade involving ERb-mediated transcriptional upregulation of hsa-miR-765
that suppresses HMGA1 protein expression as part of the mechanism underlying the tumor suppressor action of fulvestrant
in prostate cancer.
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Introduction
The normal development and malignant growth of the prostate
are regulated not only by androgens but also by estrogen [1]. The
estrogen receptor (ER)b is the principal receptor expressed in the
prostatic epithelium and in several stages of prostate cancer (PCa),
including bone metastases [2,3]. The synthetic estrogen diethyl-
stilbestrol (DES), through its androgen-deprivation action, was
once the frontline treatment for metastatic PCa [1,4]. DES
eventually lost favor because of its high cardiovascular toxicity and
thromboembolic risk [5,6], with parenteral estradiol-17b (E2)
gaining recent popularity as a therapy for metastatic, castration-
resistant PCa (CRPC) [7,8] because of its low cardiovascular
toxicity profile and protective action against osteoporosis [9].
Other selective ER modulators (e.g., tamoxifen, toremifene, and
reloxifene) have been investigated in clinical trials but found to
have limited efficacy as compared with DES [10–13]. With the
approval in 2005 of fulvestrant (ICI 182,780), a pure estrogen
receptor antagonist with no known agonistic action, for treatment
of receptor-positive metastatic breast cancer, interest in its use for
CRPC has emerged.
In preclinical models, fulvestrant has demonstrated features of a
promising therapy for PCa. In an estrogen-induced PCa model
[14–17], fulvestrant prevented the evolution of precancerous
lesions, reversed the E2-induced transcriptome [16,17], and
induced its own gene signature [16]. In DU145, a human PCa
cell line that expresses ERb and no ERa, fulvestrant suppressed
cell growth via the receptor [18] and regulated a unique set of
genes, possibly through cross-talk between ERb and NFkB [19].
Furthermore, fulvestrant suppressed the growth of DU145 and
PC-3 xenografts through an ERb-mediated KLF5 signaling
pathway [20] and also inhibited LNCaP cell growth by
downregulating the androgen receptor [21].
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In the only phase II study of fulvestrant so far conducted [22],
20 CRPC patients received a loading-dose regimen (500 mg on
day 0 and then 250 mg on day 14, day 28, and monthly
thereafter). After six months of treatment, fulvestrant was well
tolerated, although no favorable clinical or PSA response was
observed [22]. However, by increasing the loading dose in the first
month (500 mg every 14 days), the PSA level was effectively
reduced by 40–99% within 0.27–2.67 months in six of the seven
highly pretreated CRPC patients without any obvious toxicity
[23]. This latter finding lends support to conducting more research
in dose optimization and in-depth mechanistic studies of
fulvestrant as a therapy for PCa.
MicroRNAs (miRNAs) are small (17–25 nucleotides) non-
coding RNAs that regulate post-transcriptional gene expression.
Each miRNA can bind to one or more target sequences in the 39-
untranslated-region of its target transcripts and elicit degradation
of mRNA or suppression of protein translation, depending on the
degree of complementary base pairing [24]. A single miRNA
normally regulates expression of a large number of transcripts [25–
27]. Aberrant expression of specific miRNAs confers a growth
advantage to cancer cells over normal cells by disrupting multiple
oncogenic/tumor-suppressor pathways. PCa-specific miRNAs
have been identified [28–30], and some are androgen-related
[31]. To date, however, no single miRNA has been linked to
estrogens or antiestrogens in PCa.
Here, we examined the role of miRNA in mediating the action
of fulvestrant in PCa. Global profiling of miRNA expression in
DU145 cells identified hsa-miR-765 as a fulvestrant-regulated
miRNA. Promoter analyses defined a minimal sequence in the 59-
regulatory region of hsa-miR-765 that recruits ERb and that is
critical for fulvestrant regulation. The effects of the miRNA on
PCa cell growth, migration, and invasion were compared with
those of fulvestrant. The dependency of fulvestrant actions on ERb
was demonstrated by knockdown experiments. The change in
expression of hsa-miR-765 and its downstream oncogenic protein,
high-mobility group AT-hook 1 (HMGA1), was assessed in
prostatectomy specimens obtained from patients after they had
been treated with fulvestrant for one month.
Materials and Methods
Fulvestrant treatment
DU145 and PC3 cell lines were purchased from ATCC
(Manassas, VA). DU145 cells (ATCC) were maintained as
previously described [18]. PC3 (ATCC) cells were cultured in
RPMI 1640 with 10% heat-inactivated FBS (hiFBS). The identity
of each cell line has recently been authenticated by ATCC using
short tandem repeat profiling method. All cells were maintained in
5% charcoal-stripped hiFBS medium for 24 h before drug
treatment. The cells were treated with either 1026 M fulvestrant
in 0.1% or 0.1% ethanol. Control cultures were treated with
vehicle only.
MiRNA and gene expression
For miRNA profiling, total RNAs were extracted and labeled
directly using the NCode Rapid Labeling System (Invitrogen,
Grand Island, NY) and arrayed on the NCode Human miRNA
Microarray V3 (Invitrogen).
Tissue expression of miRNA was studied by extracting total
RNAs from cryosections (5–10 mm) using RNAzol RT (Molecular
Research Center, Cincinnati, OH), poly(A)-tailed and reverse
transcribed with universal RT primer using the NCode micro-
RNA first-strand cDNA kit (Invitrogen). Real-time PCR was
conducted with SYBRGreen PCR Master-Mix (Invitrogen) using
either the hsa-miR-765 specific or spliceosomal U6 small nuclear
RNA (RNU6)-specific qRT forward primer (Table S2) and a
universal reverse qPCR primer (Invitrogen).
Total RNAs were prepared with random hexamer (Invitrogen).
Ribosomal protein 3 (RPS3, Table S2) was used as the
housekeeping control. Relative gene expression was determined
by the DDCT method [32].
Clinical specimens
Patients with histologically confirmed, clinically localized PCa
were given a single intramuscular injection of 250 mg of
fulvestrant, 28 days before a scheduled radical retropubic
prostatectomy. Patients were excluded if they had a white blood
cell count ,3,000/ml, a platelet count ,100,000/ml, hemoglobin
,11 g/dl, INR.1.6, or bilirubin AST or creatinine levels .1.5
times the upper limit of normal. Patients also were excluded if they
required corticosteroids for the treatment of other systemic
diseases or had a history of congestive heart failure, active angina,
infection, or active second malignancy. All subjects had a final
Gleason sum of 6 or 7 at prostatectomy. Specimens from
untreated patients with a similar Gleason sum and all specimens
from fulvestrant-treated patients were obtained from University of
Massachusetts Medical School (UMMS) under a protocol (PI. Dr.
Maranchie) approved by the Committee for the Protection of
Human Subjects in Research and Institutional Review Board at
UMMS. All subjects provided written informed consent to
participate in this study and they were de-identified.
Knockdown of ERb
SiRNAs for ERb or scramble siRNA (Invitrogen) was trans-
fected into DU145 cells (26105) using X-tremeGENE (Roche,
Indianapolis, IN). The siRNA-treated cells were treated with
either fulvestrant or ethanol for another 2–4 days and then
subjected to real-time RT-PCR, promoter activity analysis, cell
growth assay, and F-actin staining.
59-regulatory region analyses
The 59 upstream genomic regions of hsa-miR-765 precursor
(Chr1:156,906,923–156,906,036 Accession no. NC_000001.10)
from 23208 to +100 was amplified and cloned into pGL3-basic
(Promega, Madison, WI) as pGL3-hsa-miR-765. Serial deletions
from the 59 end of the cloned sequence in the vector were
conducted to generate pGL3-miR-765-D1192 bp (DNA sequence
from 22016 to +100), pGL3-miR-765-D1766 bp (DNA sequence
from 21442 to +100), pGL3-miR-765-D2414 bp (DNA sequence
from 2792 to +100), pGL3-miR-765-D2618 bp (DNA sequence
from 2590 to +100), pGL3-miR-765-D2972 bp (DNA sequence
from 2236 to +100), and pGL3-miR-765-D3113 bp (DNA
sequence from 295 to +100). Reporter activities of other
truncated or mutated vectors in DU145 cells were determined
with or without fulvestrant and/or ERb siRNA knockdown using
the dual luciferase reporter assay system (Promega).
MiRNA targeting reporter assay
DU145 cells were transfected with luciferase reporter vector
pMIR-miR-765 that was cloned with complementary sequence of
hsa-miR-765 as perfect miR-765 target and then treated with
either hsa-miR-765 mimic or negative-control mimic. The lysates
were subjected to the dual luciferase reporter assay. The 39-
translational region of high- mobility group AT-hook 1 (HMGA1) gene
(+8026–+9332) was generated by PCR (primers in Table S2) and
cloned into pMIR-REPORT (Invitrogen) as pMIR-HMGA1-
3UTR. The hsa-miR-765 mimic (sequence in Table S2) was cloned
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into pMIR as pMIR-miR-765. The effect of the hsa-miR-765 mimic
on luciferase expression was determined by luciferase assay
(Promega), with pMIR-empty included as a control.
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) assays were performed
according to published methods [19]. In brief, DU145 cells were
treated with fulvestrant or control for 45 min. DNA-protein
complexes were crosslinked with 1% formaldehyde. Nuclear
complexes were sonicated (250–500 bp). Five micrograms of
mouse IgG (Millipore, Billerica, MA), anti-RNA polymerase II
(Millipore) or anti-ERb1 (Serotec, Raleigh, NC) antibodies were
applied for overnight immunoprecipitation. The DNA-protein
complexes were washed and eluted. Immunoprecipitated DNAs
were cleaned up, reverse-crosslinked, and purified. PCR and
realtime PCR revealed the recruitment of ERb to a sequence in
the 59-regulatory region of hsa-miR765 (primers listed in Table S2).
The 0N promoter of ERb [33] was used as a non-ERb binding
control for this experiment.
Cell-growth assay
Effects of fulvestrant or hsa-miR-765–mimic treatment on
DU145 or PC3 cell growth were determined by the CellTiter 96
Non-radioactive Cell Proliferation Assay (Promega). For HMGA1
ectopic expression experiment, full length of HMGA1 (pCMV6-
AC-HMGA1, OriGene, Rockville, MD) or a negative-control
(pCMV6-AC) were transfected into DU145 cells. The transfected
cells were enriched in G418-supplemented medium for a week.
Relative growth of DU145 cells co-treated with fulvestrant for 4
days and either HMGA1 expression or empty vector relative to the
control cells treated with ethanol and empty vector were
compared.
Flow cytometry analyses
DU145 cells were treated with fulvestrant/ethanol or hsa-miR-
765 mimic/negative-control mimic for 2 days. The treated cells
were analyzed according to published protocols [32].
Western blot analyses
Five micrograms of protein from cell lysate were electropho-
resed on 10–12.5% SDS-PAGE and subjected to Western blot
analysis. Primary antibodies listed in Table S3 were used to detect
protein levels.
Migration and invasion assays
DU145 or PC3 cells were treated with fulvestrant or hsa-miR-
765 mimic and their respective controls for 2 days. Wound-healing
assays were performed as previously reported [34]. DU145 cells
were pretreated with fulvestrant or ethanol for 5 h before
migration and invasion assays were performed [34].
Filamentous-actin (F-actin) staining
F-actin in fulvestrant- or ethanol-treated DU145 cultures
subjected to RNAi-mediated knockdown of ERb, hsa-miR-765-
mimic transfection, or control treatment were visualized as
previously described [34]. In brief, the fulvestrant- and ethanol-
treated control DU145 cells with either ERb siRNA or negative-
control siRNA were stained with TRITC-conjugated phalloidin,
and the fluorescence images were captured.
Computational prediction of miRNA targets
MiRanda/mirSVR [35] (http://www.microrna.org), TargetS-
can r5.2 [36] (http://www.targetscan.org), RNAhybrid [37], and
EIMMo2 [38] were used to predict the putative targets of hsa-miR-
765. Genomic alignments, BLAT (http://www.ensembl.org), were
used for additional validation of predicted sites.
Immunostaining of HMGA1 and AR
Frozen sections (5 mm) of PCa specimens from patients treated
or not treated with fulvestrant prior to prostatectomy were fixed in
3% formaldehyde at room temperature and then with methanol at
220uC. HMGA1 and AR was immunodetected with 1:100 anti-
HMGA1 antibody (sc 8982, Santa Cruz Biotechnology, Santa
Cruz, CA) and anti-AR respectively (sc 816, Santa Cruz
Biotechnology, Santa Cruz, CA) according to published protocols
[39]. Immunopositivity was determined by the percentage of
positive signal (nuclear or cytoplasmic) in Gleason grade 3/4 foci.
Results
A. Fulvestrant inhibits cell growth, cell-cycle progression,
migration, and invasion in an ERb-dependent manner
Fulvestrant inhibited the growth of DU145 cells by 40% and
PC-3 cells by 30% through an ERb-dependent pathway
(Figure 1A, Figure S1A) and arrested cell division at the G2/M
phase, as indicated by a significant decrease in the G0/G1 cell
population and an accumulation of G2/M cells (Figure 1B). The
disruption in cell-cycle progression was accompanied by enhanced
expression of the G2/M markers cyclin A (G2), cyclin B (M), and
phosphorylated cdc2 (G2) but not of the S-phase markers cyclin E
and cdc25C (Figure 1C).
Fulvestrant inhibited cell migration in the wound-healing assay
(Figure 1D), and transwell migration (Figure 1E, left panel) and
cell invasiveness in the transwell invasion assay (Figure 1E, right
panel) by,40% (p,0.01, n= 3) in DU145 cells (Figure 1E) as well
as in PC-3 cells (Figure S2). Treatment with fulvestrant
significantly reduced the percentage of filopodial cells from
90.1% to 55.9% (p,0.005, n = 5) and of cells with intense stress
fiber from 96.4% to 64.2% (p,0.001, n= 5) (Figure 1F). RNAi-
mediated knockdown of ERb effectively reversed the fulvestrant-
induced inhibition (Figure 1F).
B. Fulvestrant upregulates hsa-miR-765 expression in PCa
cells
Among the 211 detectable miRNAs, 6 highly abundant
miRNAs including hsa-miR-185, hsa-let-7b, hsa-miR-765, hsa-
let-7a, hsa-miR-601, and hsa-miR-768-5p (.300 relative normal-
ized signal intensity) were upregulated after fulvestrant-treatment
(.2-fold; p,0.005) (Figure 2A). Hsa-miR-765 was one of the miRs
that exhibited the greatest relative increase (3.8-fold) and greatest
absolute level of expression in fulvestrant-treated DU145 cells
(Table S1). Fulvestrant also induced a significant increase in the
expression of this miR in PC3 cells in an ERb-dependent manner
(Figure 2B, Figure S1B).
C. Hsa-miR-765 inhibits cell growth, cell-cycle
progression, migration and invasion
A hsa-miR-765 mimic or a negative-control was expressed in
DU145 cells carrying the luciferase reporter vector pMIR-miR-765.
Ectopic expression of the hsa-miR-765 mimic, but not the negative-
control, effectively suppressed luciferase activity by .70% in
DU145 cells (Figure 3A). Overexpression of the hsa-miR-765
mimic in DU145 cells induced inhibition of cell growth (40%;
Figure 3B) and cell-cycle arrest at G2/M (G0/G1 to G2/M ratio
decreased from 3.560.26 to 2.760.10, p=0.0074) (Figure 3C)
and upregulated the expression of cyclin A, cyclin B, and
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Figure 1. Fulvestrant inhibits DU145 cell growth, migration, and invasion. (A) Fulvestrant induces growth inhibition of DU145 cells via an
ERb-dependent mechanism. Growth of the fulvestrant-treated DU145 cells with or without ERb siRNA knockdown for 4 days relative to the ethanol-
treated control cells with negative-control siRNA are presented and compared (n = 8). ERb expression was also knocked down by another siRNA
(siRNA#2) and the similar results were obtained (Figure S5). (B) Fulvestrant induces DU145 cell-cycle arrest at G2/M phase. Representative DNA
histograms of 48 hrs fulvestrant -or ethanol- (control) treated cells and percentage distributions of the cells at G0/G1 and G2/M phases (n = 3) are
presented and compared. (C) Fulvestrant induces expression of G2/M markers. DU145 cells were treated with fulvestrant or ethanol for 2 days
(control) and cell cycle markers were determined by Western blot analysis. Two independent experiments were performed and one representative set
of data was presented. (D) Fulvestrant suppresses cell migration. A wound-healing assay was performed on the fulvestrant- and ethanol (EtOH)-
treated DU145 cells (n = 3). Representative micrographs of the fulvestrant- and ethanol-treated cell cultures with scratches at 0 h and after 16 h are
shown. The wound is marked by dotted lines. (E) Fulvestrant inhibits transwell migration (left panel) and invasion (right panel) in DU145 cells (n = 3)
after 5 hrs of fulvestrant treatment. (F) Reductions of filopodial cells and cells with intense stress fibers by fulvestrant (treated with 48 hrs) via an ERb-
dependent mechanism. Representative micrographs and the percentages of the cells with intense stress fibers and the filopodial cells (n = 3) are
presented. Student t-test was performed to determine significance with a cutoff p value of 0.05. ** p,0.01; bars = S.D.
doi:10.1371/journal.pone.0098037.g001
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phosphorylated-cdc2 but not cyclin E or cdc25C (Figure 3D).
Finally, it decreased cell migration and invasiveness (,80%;
Figure 3E), and the formation of filopodia/intense stress fiber
(Figure 3F) at levels greater than or comparable to those induced
by fulvestrant (see Figures 1C & 1D). Overall, the actions of hsa-
miR-765 in DU145 cells are highly similar to those of fulvestrant.
In addition to DU145 cells, the inhibitory effects of has-miR-765
mimic were also observed in PC-3 cells (Figure S3).
D. Fulvestrant induces upregulation of hsa-miR-765
expression via recruitment of ERb to a putative
regulatory element
DU145 cells were subjected to siRNAs-mediated knockdown of
ERb prior fulvestrant treatment. SiRNA effectively knocked down
ERb expression (Figure S4). This knockdown completely blocked
fulvestrant-induced enhancement of hsa-miR-765 expression
(Figure 4A) and abolished the transactivation activities of
fulvestrant on a 59-regulatory sequence of hsa-miR-765 (between
23208 and +100; 3.3 kb) (Figure 4B). Serial deletion analysis
identified a 141 bp sequence (between 2236 and 295) within the
3.3-kb 59-regulatory sequence as essential in mediating the
stimulatory effect of fulvestrant on hsa-miR-765 transcription.
ChIP assays further demonstrated recruitment of ERb to this short
sequence following fulvestrant stimulation (Figure 4D). These data
support a role of ERb in mediating fulvestrant-induced hsa-miR-
765 upregulation.
E. HMGA1 is a target of hsa-miR-765
Bioinformatic analyses with multiple miRNA target prediction
programs suggested HMGA1 as a target of hsa-miR-765; a
conserved recognition site at +8982 to +9002 with 222.6 kcal/
mol of minimum free energy was predicted (Figure 5A, Table S4).
Reporter assays demonstrated that transfection of hsa-miR-765
mimic, but not of a negative-control mimic, significantly decreased
HMGA1 39 UTR-dependent luciferase activity (Figure 5B); no such
difference was observed in DU145 cells carrying the pMIR-empty
vector. Importantly, transfection of the hsa-miR-765 mimic
completely blocked the expression of HMGA1 protein (Figure 5C
upper panel), along with a slight reduction in the mRNA level
(Figure 5C, lower panel). Of interest, treatment with fulvestrant
also effectively shut down the expression of HMGA1 protein
(Figure 5D). These data support an inhibitory role of hsa-miR-765
on HMGA1 expression at the protein level and a mediator role in
fulvestrant action on PCa cells. Finally, ectopic expression of
HMGA1 effectively reduced the growth inhibitory effect of
fulvestrant on DU145 cells (Figure 5E), a finding consistent with
the reported oncogenic action of HMGA1 in the prostate [40].
F. Hsa-miR-765 is elevated but HMGA1 protein is reduced
in fulvestrant-treated PCa specimens
Prostatectomy tissues were obtained from patients with localized
PCa who received or not received fulvestrant treatment (250 mg,
i.m. 28 days before prostatectomy). Real time RT-PCR analyses
showed upregulation of hsa-miR-765 mRNA (2.7-fold, p,0.05,
n = 7) in the PCa specimens from fulvestrant-treated patients as
compared with those from untreated controls (n = 7) (Figure 6A).
In contrast, immunohistological analyses revealed a marked
reduction in HMGA1 immunopositivity in specimens from
fulvestrant-treated patients (Figure 6B). HMGA1 was localized
primarily in the nuclei of PCa cells in cancer foci, with only weak
cytoplasmic staining in stromal cells. Immunostaining was
negligible in fulvestrant-treated specimens in almost all cancer
foci (Figure 6C, p,0.01, n = 5). Androgen receptor was previously
shown to be downregulated by fulvestrant in a rodent [41] and a
cell model [21]. Here, we showed AR was also significantly
downregulated in our clinical study (Figure 6B and C). However,
as we reported previously, ERb was significant loss in these foci
[33] and fulvestrant treatment did not affect the ERb level (data
not shown). These results, taken together, indicate that fulvestrant
enhanced hsa-miR-765 expression but suppressed HGMA1 and
AR protein expression in PCa specimens from treated-patients.
Figure 2. Fulvestrant upregulates hsa-miR-765 expression in
DU145 cells. (A) Hsa-miR-765 is highly expressed in fulvestrant-treated
DU145 cells. Total RNAs of treated cells were labeled directly and
arrayed on the NCode Human miRNA Microarray. The median- and
linear regression-normalized data are presented in a scatterplot. (B) Hsa-
miR-765 is induced by fulvestrant in two prostate cancer cell lines. The
hsa-miR-765 in the fulvestrant- and ethanol-treated control DU145 and
PC-3 cells was quantified by miRNA qRT-PCR analysis. Relative fold
changes between the expression of hsa-miR-765 in the fulvestrant-
treated and control cells are presented. Student t-test was performed to
determine their significance using a cutoff p value of 0.05 (n = 3). **p,
0.01; bars = S.D.
doi:10.1371/journal.pone.0098037.g002
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Discussion
In the present study, we identified a novel mechanism of action
of fulvestrant that is mediated by ERb-dependent upregulation of
hsa-miR765, a miRNA with strong anti-PCa action. Deletion
analysis identified a short sequence that interacts with fulvestrant
(,140 bp) within a 3.3 kb 59-regulatory region of hsa-miR765.
Interestingly, on the basis of prediction analysis, this short
sequence does not harbor any known ERb interacting elements.
Yet, fulvestrant can promote recruitment of ERb to the sequence.
One possible explanation is that fulvestrant recruits the receptor
via tethering [19,20,42–44] but to an unknown tethering partner
of ERb, whose identity remains to be uncovered.
Bioinformatics analyses of the ERb binding region have been
performed based on TRANSFAC database. No consensus full or
half ERE was found. Furthermore, no previously reported ERb
tethering sites such as SP1, AP1 and FOXA1 were found.
However, a putative PAX5 binding site was identified. PAX5 is a
transcription factor responsible for regulating B cell lineage. We
have performed multiple ChIP and re-ChIP assays (data not
shown) and could not establish either recruitment of PAX5 to this
region nor demonstrate tethering of ERb to the putative PAX5
Figure 3. Hsa-miR-765 suppresses DU145 cell growth, migration, and invasion. (A) Hsa-miR-765 mimic effectively recognizes reporter with
complementary sequence of hsa-miR-765 in DU145 cells. Fold changes of luciferase activities of the hsa-miR-765 mimic treated cells relative to the
cells treated with the negative-control mimic are presented (n = 3). Transfection reagents were used as control. (B) Hsa-miR-765mimic reduces DU145
cell growth. MTS assay was performed on the cells treated with hsa-miR-765mimic or negative-control mimic or transfection control for 4 days (n = 8).
(C) Hsa-miR-765 mimic significant reduces G0/G1 to G2/M ratio in DU145. Representative DNA histograms (n = 3) are presented. (D) Hsa-miR-765
mimic treatment causes up-regulation of cyclin A, cyclin B, and phosphorylated-cdc2 expression in DU145 cells. Protein expression levels of cell cycle
regulator proteins were determined by Western blot analyses. Two independent experiments were performed and one representative set of data was
presented. (E) Hsa-miR-765 mimic suppresses DU145 cell migration and invasion as shown in transwell migration assay (top left) and invasion assay
(top right), respectively. Representative micrographs of the cells after transwell migration (top left) or invasion assay (top right) are presented. Fold
changes of migration (bottom left) and invasion (bottom right) of DU145 cells with either hsa-miR-765mimic or negative-control mimic relative to the
control cells with negative-control mimic are presented (n = 3). (F) Hsa-miR-765 mimic significantly reduces stress fibers and filopodia formations in
DU145 cells. Representative micrographs and the percentages of the cells with intense stress fibers and the filopodial cells (n = 3) are presented.
Student’s t-test was used for comparisons with a cutoff p value of 0.05. ** p,0.01; bar = S.D.
doi:10.1371/journal.pone.0098037.g003
Hsa-miR-765 Expression in Fulvestrant-Treated Prostate Cancer
PLOS ONE | www.plosone.org 6 May 2014 | Volume 9 | Issue 5 | e98037
binding site. This is not necessary a surprise finding because the
characterization of cristrome for ERb has not been fully
completed.
MiRNAs function as negative post-transcriptional regulators for
gene expression through imperfect binding to the 39-UTR of
target genes, causing translational repression and/or rapid
transcript degradation [29,45]. In this study, we identified and
Figure 4. ERb is involved in fulvestrant-induced upregulation of hsa-miR-765 expression. (A) ERb siRNA knockdown blocks fulvestrant-
induced upregulation of hsa-miR-765 expression in DU145 cells. Expression levels of hsa-miR-765 determined by qRT-PCR analysis of the fulvestrant-
treated cells with ERb-siRNA (siERb) or scramble negative-control (siNeg) were compared (n = 3). (B) SiRNA knockdown of ERb blocks fulvestrant-
induced transactivation of the 59 upstream regulatory region of hsa-miR-765 in DU145 cells. 59 upstream regulatory region of hsa-miR-765 was cloned
into a luciferase vector. The reporter activities with ERb-knockdown (siERb) or scramble negative-control (siNeg) in the presence of fulvestrant were
compared (n = 3). (C) Deletion mapping analysis defines a fulvestrant-responsive segment in hsa-miR-765 regulatory region in DU145 cells. The 59
upstream DNA sequence of hsa-miR-765 from nt. 23208 to +100 was analyzed using luciferase reporter system. Serial deletions from the 59 end of
the cloned sequence in the vector were conducted. Reporter activities were compared between the fulvestrant-treated (Fulvestrant) and control
(ETOH) cells for each reporter vector (n = 3). (D) Fulvestrant-induces recruitment of ERb onto the putative hsa-miR-765 regulatory region. Chromatin-
immunoprecipitation revealed the recruitment of ERb to a sequence in the 59-regulatory region of hsa-miR765. Mouse IgG and RNA polymerase II
serve as negative and positive control, respectively. Fulvestrant induced 17 fold increase in ERb recruitment when compared with non-ERb binding
region (the 0N promoter of ERb [33,41]). Student’s t-test was performed to determine significance of between groups using a cutoff p value of 0.05.
** p,0.01; bar = S.D.
doi:10.1371/journal.pone.0098037.g004
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validated HMGA1 as a target of hsa-miR-765 in PCa cells.
Consistent with our finding is the significant reduction of DU145
cell growth by RNAi-mediated knockdown of HMGA1 [40]. In
contrast, ectopic expression of HMGA1 in non-metastatic
Dunning PCa cells increased in vitro and in vivo growth and
enhanced in vitro invasion [46]. In clinical PCa tissues, high
expression of HMGA1 was associated with high Gleason grades,
invasiveness, and recurrence [47,48]. Collectively, these findings
implicated HMGA1 as playing an oncogenic role in PCa that can
be blocked by fulvestrant or a hsa-miR-765 mimic.
Current investigations of miRNAs in PCa focused primarily on
the identification of aberrantly expressed miRNAs as diagnosis/
prognosis biomarkers [28,29,45,49]. However, a more interesting
study would address the identification of miRNAs that can be used
to predict therapeutic responses. To date, only a few studies have
addressed the modulation of miRNA expression in PCa cells in
response to hormones (androgen ablation therapy) [49–52] and
Figure 5. HMGA1 is a direct target of hsa-miR-765. (A) The 39UTR of HMGA1 from +8910 to +8929 is predicted to be hsa-miR-765 binding site. (B)
Hsa-miR-765 interacts with 39UTR of HMGA1 in a targeting reporter assay. DU145 cells were transfected with either pMIR-empty or pMIR-HMGA1-
3UTR in which 39 UTR of HMGA1 (+8026–+9332) was cloned into the 39 end of luciferase. Reporter activities of the pMIR-HMGA1-3UTR transfected
cells treated with hsa-miR-765 mimic or negative-control mimic are compared (n = 3). (C) Hsa-miR-765 mimic reduced HMGA1 protein expression in
DU145 cells. Protein and mRNA levels of HMGA1 in the hsa-miR-765 mimic- and negative-control mimic-treated cells were determined by Western
blot analysis (upper) and real-time RT-PCR analysis (lower), respectively. Results from miR-765 mimic vs negative control mimic are compared (n = 3).
(D) Fulvestrant reduces HMGA1 protein expression in DU145 cells. Protein level of HMGA1 and b-actin in the fulvestrant-treated and ethanol-treated
control (CTL) cells were determined by Western blot analysis. (E) Ectopic expression of HMGA1 blocks fulvestrant-induced DU145 cell growth
inhibition. The relative cell growth was determined after 4 days of treatment with fulvestrant or ethanol after stable transfection of HMGA1 (or empty
vector for control) for a week. Protein levels of HMGA1 were shown in Figure S6. The cell growth of fulvestrant-treated cells with HMGA1
overexpression vs empty vector are compared (n = 8). Student’s t-test was performed to determine significance between groups using a cutoff p
value of 0.05. **p,0.01; bar = S.D.
doi:10.1371/journal.pone.0098037.g005
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radiation [53,54]. Our findings of the anti-PCa action of
fulvestrant via upregulation of hsa-miR-765 provide new mecha-
nistic insights to the action of this antiestrogen and an invaluable
tool for monitoring fulvestrant-responsiveness in patients. Future
identification of additional fulvestrant-regulated miRNAs and
their downstream targets would enhance the development of
effective PCa therapies beyond the antiestrogen.
Preclinical studies demonstrated that fulvestrant is effective in
inhibiting the growth of PCa cells in culture [18–21] and as
xenografts [20] and in preventing the development of PCa in
animal models [17]. However, the mechanism of action of
fulvestrant remains unclear, except for a few earlier reports
suggesting that ERb is its key mediator [18–20]. In this study, we
confirmed that fulvestrant exerts antitumor effects on DU145 cells
via ERb signaling. This finding is consistent with several reports
on the anti-PCa action of ERb, such as inhibition of epithelial-
mesenchymal transition [55], downregulation of VEGF-A [55]
and TMPRSS2-ERG [56], reduction of PC3 cell migration and
invasion in vitro [39], and growth of DU145 and PC3 xenografts in
nude mice [20]. Other proposed mechanisms of action of
fulvestrant include cross-talk of ERb with the NFkB [19] or the
KLF5 [20] signaling pathways to mediate cell death or anoikis,
respectively, as well as suppression of androgen-receptor expres-
sion [21,41] and its action [21].
Although no favorable clinical outcome was noted in the only
fulvestrant clinical II trial, of 20 patients with CRPC, using a
loading dose regimen (500 mg on day 0 and 250 mg thereafter) for
six months [22], a smaller study using a higher dose in the first
month (500 mg every 14 days) produced a marked reduction in
PSA (40–99%) in six of the seven CRPC patients [23]. Our clinical
study was the only one that gave fulvestrant (250 mg) 28 days
before prostatectomy to patients with PCa who had clinically
localized low-grade disease. It was gratifying to observe a
significant elevation in hsa-miR-765 and an almost complete loss
of HMGA1 and significant reduction of AR expression in PCa
tissues of treated-patients. These findings suggest that fulvestrant
given in a neoadjuvant setting can elicit tumor-suppressing action.
The question of whether fulvestrant given as neoadjuvant therapy
can prevent or delay the recurrence of PCa remains an area
worthy of future exploration.
In conclusion, hsa-miR-765 is a novel fulvestrant-induced and
ERb-associated miRNA in PCa and it targets an oncogenic
protein HMGA1. These findings contribute to new insights on the
mode of action of fulvestrant and the potential of using miRNA for
monitoring drug responsiveness as well as for future therapeutics
development. They help promote the use of this antiestrogen for
CRPC patients for whom no curative treatment is currently
available and raise the possibility of using fulvestrant in
Figure 6. Significant reduction of HMGA1 protein correlates
with enhanced expression of hsa-miR-765 in fulvestrant-treated
clinical PCa specimens. (A) Higher level of hsa-miR-765 is detected in
fulvestrant-treated clinical PCa specimens. Relative fold changes
between expression of hsa-miR-765 in the fulvestrant-treated (n = 7)
and untreated (n = 7) clinical specimen are presented. Student’s t-test
was performed to determine significance between two groups. *p,
0.05; bar = S.E.M. (B) Nuclear expression of HMGA1 and AR is reduced in
fulvestrant-treated clinical PCa specimens. HMGA1 immunostaining was
performed in the clinical PCa specimens from the fulvestrant-treated
(n = 5) and untreated (n = 5) patients. Representative micrographs
(1006) are shown. In upper panel, a magnified view (4006) of a
selected region (dashed rectangle) in each micrograph is shown as a
small insert to show the immunostaining of HGMA1 in the nuclei of
Gleason grade 3/4 cancer foci. Imunnopositivity of nuclear AR is
reduced in fulvestrant-treated Gleason grade 3/4 foci as shown in lower
panel (4006). (C) Expression of both HMGA1 and AR is significantly
reduced in fulvestrant-treated clinical PCa specimens when compared
with their respective untreated samples (*p,0.05; **p,0.01; n = 9 (from
5 patients) for untreated samples; n = 10 (from 5 patients) for
fulvestrant-treated samples, bar = S.E.M).
doi:10.1371/journal.pone.0098037.g006
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preventing/slowing progression for locally confirmed PCa. Iden-
tification of additional miRNAs and their targets regulated by
estrogens and antiestrogens may afford new opportunities for
devising low toxicity therapies for PCa.
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